HeimME • NASDAQ
add
23andMe Holding Co.
3,11 $
Eftir lokun(3,54%)+0,11
3,22 $
Lokað: 22. nóv., 18:26:25 GMT-5 · USD · NASDAQ · Lagalegir fyrirvarar
Við síðustu lokun
3,23 $
Dagbil
2,99 $ - 3,21 $
Árabil
2,66 $ - 20,20 $
Markaðsvirði
74,94 m. USD
Meðalmagn
404,88 þ.
V/H-hlutf.
-
A/V-hlutfall
-
Aðalkauphöll
NASDAQ
Í fréttum
Fjármál
Rekstrarreikningur
Tekjur
Nettótekjur
(USD) | sep. 2024info | Breyting á/á |
---|---|---|
Tekjur | 44,07 m. | -11,86% |
Rekstrarkostnaður | 81,33 m. | -17,18% |
Nettótekjur | -59,10 m. | 21,48% |
Hagnaðarhlutfall | -134,11 | 10,91% |
Hagnaður á hvern hlut | — | — |
EBITDA | -54,96 m. | 21,06% |
Virkt skatthlutfall | 0,07% | — |
Efnahagsreikningur
Heildareignir
Heildarskuldir
(USD) | sep. 2024info | Breyting á/á |
---|---|---|
Reiðufé og skammtímafjárfestingar | 126,60 m. | -50,62% |
Heildareignir | 318,94 m. | -60,19% |
Heildarskuldir | 217,01 m. | 23,31% |
Eigið fé alls | 101,93 m. | — |
Útistandandi hlutabréf | 26,12 m. | — |
Eiginfjárgengi | 0,82 | — |
Arðsemi eigna | -42,89% | — |
Ávöxtun eigin fjár | -75,30% | — |
Peningaflæði
Breyting á handbæru fé
(USD) | sep. 2024info | Breyting á/á |
---|---|---|
Nettótekjur | -59,10 m. | 21,48% |
Handbært fé frá rekstri | -40,93 m. | 28,34% |
Reiðufé frá fjárfestingum | -2,70 m. | 2,63% |
Reiðufé frá fjármögnun | 260,00 þ. | -83,68% |
Breyting á handbæru fé | -43,37 m. | 25,18% |
Frjálst peningaflæði | -12,82 m. | 59,90% |
Um
23andMe Holding Co. is an American personal genomics and biotechnology company based in South San Francisco, California. It is best known for providing a direct-to-consumer genetic testing service in which customers provide a saliva sample that is laboratory analysed, using single nucleotide polymorphism genotyping, to generate reports relating to the customer's ancestry and genetic predispositions to health-related topics. The company's name is derived from the 23 pairs of chromosomes in a diploid human cell.
Founded in 2006, 23andMe soon became the first company to begin offering autosomal DNA testing for ancestry, which all other major companies now use. Its saliva-based direct-to-consumer genetic testing business was named "Invention of the Year" by Time in 2008.
The company had a previously fraught relationship with the United States Food and Drug Administration due to its genetic health tests; as of October 2015, DNA tests ordered in the US include a revised health component, per FDA approval. 23andMe has been selling a product with both ancestry and health-related components in Canada since October 2014, and in the UK since December 2014. Wikipedia
Framkvæmdastjóri
Stofnsett
apr. 2006
Höfuðstöðvar
Vefsvæði
Starfsfólk
571